Skip to content
No PriorsNo Priors

No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

On this week’s episode of No Priors, Sarah Guo is joined by leading members of the teams at Vevo Therapeutics and the Arc Institute – Nima Alidoust, CEO/Co-Founder at Vevo Therapeutics; Johnny Yu, CSO/Co-Founder at Vevo Therapeutics; Patrick Hsu, CEO/Co-Founder at Arc Institute; Dave Burke, CTO at Arc Institute; and Hani Goodarzi, Core Investigator at Arc Institute. Predicting protein structure (AlphaFold 3, Chai-1, Evo 2) was a big AI/biology breakthrough. The next big leap is modeling entire human cells—how they behave in disease, or how they respond to new therapeutics. The same way LLMs needed enormous text corpora to become truly powerful, Virtual Cell Models need massive, high-quality cellular datasets to train on. In this episode, the teams discuss the groundbreaking release of the Tahoe-100M single cell dataset, Arc Atlas, and how these advancements could transform drug discovery. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @Nalidoust | @IAmJohnnyYu | @PDHsh | @Davey_Burke | @Genophoria Show Notes: 0:00 Introduction 1:40 Significance of Tahoe-100M dataset 4:22 Where we are with virtual cell models and protein language models 10:26 Significance of perturbational data 17:39 Challenges and innovations in data collection 24:42 Open sourcing and community collaboration 33:51 Predictive ability and importance of virtual cell models 35:27 Drug discovery and virtual cell models 44:27 Platform vs. single hypothesis companies 46:05 Rise of Chinese biotechs 51:36 AI in drug discovery

Sarah GuohostJohnny YuguestNima AlidoustguestPatrick HsuguestDave BurkeguestHani GoodarziguestElad Gilhost
Feb 25, 202557mWatch on YouTube ↗

Episode Details

EPISODE INFO

Released
February 25, 2025
Duration
57m
Channel
No Priors
Watch on YouTube
▶ Open ↗

EPISODE DESCRIPTION

On this week’s episode of No Priors, Sarah Guo is joined by leading members of the teams at Vevo Therapeutics and the Arc Institute – Nima Alidoust, CEO/Co-Founder at Vevo Therapeutics; Johnny Yu, CSO/Co-Founder at Vevo Therapeutics; Patrick Hsu, CEO/Co-Founder at Arc Institute; Dave Burke, CTO at Arc Institute; and Hani Goodarzi, Core Investigator at Arc Institute. Predicting protein structure (AlphaFold 3, Chai-1, Evo 2) was a big AI/biology breakthrough. The next big leap is modeling entire human cells—how they behave in disease, or how they respond to new therapeutics. The same way LLMs needed enormous text corpora to become truly powerful, Virtual Cell Models need massive, high-quality cellular datasets to train on. In this episode, the teams discuss the groundbreaking release of the Tahoe-100M single cell dataset, Arc Atlas, and how these advancements could transform drug discovery. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @Nalidoust | @IAmJohnnyYu | @PDHsh | @Davey_Burke | @Genophoria Show Notes: 0:00 Introduction 1:40 Significance of Tahoe-100M dataset 4:22 Where we are with virtual cell models and protein language models 10:26 Significance of perturbational data 17:39 Challenges and innovations in data collection 24:42 Open sourcing and community collaboration 33:51 Predictive ability and importance of virtual cell models 35:27 Drug discovery and virtual cell models 44:27 Platform vs. single hypothesis companies 46:05 Rise of Chinese biotechs 51:36 AI in drug discovery

SPEAKERS

  • Sarah Guo

    host
  • Johnny Yu

    guest
  • Nima Alidoust

    guest
  • Patrick Hsu

    guest
  • Dave Burke

    guest
  • Hani Goodarzi

    guest
  • Elad Gil

    host

EPISODE SUMMARY

In this episode of No Priors, featuring Sarah Guo and Johnny Yu, No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute explores tahoe 100 launches virtual cell era, redefining AI-driven drug discovery The episode features leaders from Vevo Therapeutics and the Arc Institute announcing Tahoe 100, a 100‑million–cell single‑cell RNA sequencing dataset, paired with Arc’s 230‑million–cell SC Basecamp to form a 330‑million–cell Virtual Cell Atlas.

RELATED EPISODES

Amex Global Business Travel: The World’s First AI Take Private with Long Lake CEO Alexander Taubman

Amex Global Business Travel: The World’s First AI Take Private with Long Lake CEO Alexander Taubman

Baseten CEO Tuhin Srivastava on Custom Models, and Building the Inference Cloud

Baseten CEO Tuhin Srivastava on Custom Models, and Building the Inference Cloud

No Priors Ep. 27 | With Sarah Guo & Elad Gil

No Priors Ep. 27 | With Sarah Guo & Elad Gil

No Priors Ep. 105 | With Director of the Center of AI Safety Dan Hendrycks

No Priors Ep. 105 | With Director of the Center of AI Safety Dan Hendrycks

No Priors Ep. 6 | With Daphne Koller from Insitro

No Priors Ep. 6 | With Daphne Koller from Insitro

No Priors Ep. 5 | With Huggingface’s Clem Delangue

No Priors Ep. 5 | With Huggingface’s Clem Delangue

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome